[1] BLACK J G. Microbiology: Principles and explorations[M]. 8th ed. Hoboken New Jersey:John Wiley & Sons, 2012.

[2] BOUCHER H W, TALBOT G H, BRADLEY J S, et al. Bad bugs, no drugs: no ESKAPE!An update from the Infectious Diseases Society of America[J]. Clinical Infectious Diseases,2009, 48(1): 1-12.

[3] WILSON J W, ESTES L L. Mayo clinic antimicrobial therapy: quick guide[M]. New York:Oxford University Press, 2011.

[4] US Department of Health and Human Services. Antibiotic resistance threats in the United States, 2013[J]. Centers for Disease Control and Prevention, 2013.

[5] SHETTY N, TANG J W, ANDREWS J. Infectious Disease: Pathogenesis, Prevention and Case Studies [M]. Chichester, UK: Wiley-Blackwell, 2009.

[6] HARRIS S R, FEIL E J, HOLDEN M T G, et al. Evolution of MRSA during hospital transmission and intercontinental spread[J]. Science, 2010, 327(5964): 469-474.

[7] DE COSTA A, MAVALANKAR D. New Delhi metallo-β-lactamase 1[J]. The Lancet Infectious Diseases, 2010, 10(11): 752.

[8] HAMMERUM A M, TOLEMAN M A, HANSEN F, et al. Global spread of New Delhi metallo-β-lactamase 1[J]. The Lancet infectious diseases, 2010, 10(12): 829-830.

[9]汪复，朱德妹，胡付品，等. 2012年中国CHINET细菌耐药性监测[J].中国感染与化疗杂志，2013，13(5): 321-330.

[10]张辉，张小江，徐英春，等. 2011年中国CHINET不动杆菌属细菌耐药性监测[J].中国感染与化疗杂志，2013，13(5): 392-397.

[11] DENYER S P, HODGES N, GORMAN S P. Hugo and Russell’s pharmaceutical microbiology[M]. Hoboken New Jersey: John Wiley & Sons, 2008.

[12]吕吉云，曲芬.多重耐药微生物及防治对策[M].北京：人民军医出版社，2011.

[13]汪复，张婴元.实用抗感染治疗学[M]. 2版.北京：人民卫生出版社，2012.

[14]胡必杰，刘荣辉，陈文森. SIFIC感染预防与控制临床实践指引（2013年）[M].上海：上海科学技术出版社，2013.

[15]胡必杰，宗志勇.医院感染预防与控制最佳实践丛书:多重耐药菌感染控制最佳实践[M].上海：上海科学技术出版社，2012.

[16]胡必杰，陆群.医院感染预防与控制最佳实践丛书:手卫生最佳实践[M].上海：上海科学技术出版社，2013.

[17]陆德源.医学微生物学[M]. 5版.北京：人民卫生出版社，2001.

[18]闻玉梅.精编现代医学微生物学[M].上海：复旦大学出版社，2002.

[19]倪语星，洪秀华.细菌耐药性监测与抗感染治疗[M].北京：人民军医出版社，2002.

[20]郑宝英，张杰.抗生素的联合用药[J].中国抗生素杂志，2007，32(6): 324-328.

[21] World Health Organization. WHO global strategy for containment of antimicrobial resistance[EB/OL].http://apps.who.int/iris/bitstream/handle/10665/66860/WHO_CDS_CSR_DRS_2001.2.pdf?sequence=1.2001.

[22]肖永红，王进，赵彩云. 2006—2007年Mohnarin细菌耐药监测[J].中华医院感染学杂志，2008，18(8): 1051-1056.

[23]王菊仙，冯连顺.抗菌药物研发进展[J].国外医药：抗生素分册，2010 (1): 13-18.

[24] KUMARASAMY K K, TOLEMAN M A, WALSH T R, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study[J]. The Lancet infectious diseases, 2010, 10(9): 597-602.

[25] TAUBES G. The bacteria fight back[J]. Science, 2008, 321(5887): 356-361.

[26]魏明.超级细菌战[J].大自然探索，2003 (2): 68-72.

[27]孙红妹，薛冠华.新发现“NDM-1超级细菌”的流行情况及耐药机制[J].中华儿科杂志，2011，49(1): 37-40.

[28]李春辉，吴安华. MDR，XDR，PDR多重耐药菌暂行标准定义——国际专家建议[J].中国感染控制杂志，2014，13(1): 62-64.

[29] HE J, GU D, WU X, et al. Major causes of death among men and women in China[J]. New England Journal of Medicine, 2005, 353(11): 1124-1134.

[30] WHO. Antimicrobial resistance: global report on surveillance [EB/OL]. http://www.who.int/drugresistance/documents/surveillancereport/en/. 2014.